Over the past several decades, multiple treatment approaches to managing BRAF-mutant melanoma have been developed, including BRAF inhibitors, BRAF/MEK inhibitor combinations, anti-PD-1 therapy, and anti-CTLA4 therapy. This evidence concerns the gene MAP2K7 and melanoma.